IVAX recall
This article was originally published in The Tan Sheet
Executive Summary
IVAX Pharmaceuticals is issuing a voluntary recall of Goldline Extra Strength Genapap and Extra Strength Genebs (both 500 mg acetaminophen) in caplet and tablet form, FDA announces May 2. The Miami, Fla.-based firm is recalling 30 lots due to a labeling error, according to the agency. The product labels should indicate that usage is not to exceed eight tablets/caplets in a 24-hour period; however, the erroneous label indicates not to exceed 12 tablets/caplets in a 24-hour period. If more than eight tablets/caplets are ingested in a 24-hour period, patients may face an increased risk of acetaminophen toxicity to the liver, FDA notes. Consumers are urged to "cease usage and return the product to the location of purchase." Retailers and wholesalers are encouraged to return all unsold lots to IVAX...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.